Evidence map›Paper›PMID 30932340›Full record

ArticlePharmaceutical statistics2019

Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI: 10.1002/pst.1873.

Andreas Krause, Charlotte Kloft, Wilhelm Huisinga, Mats Karlsson, José Pinheiro, Robert Bies, James Rogers, France Mentré, Bret J Musser, ASA Special Interest Group on Statistics and Pharmacometrics/ASA Special Interest Group on Statistics and Pharmacometrics (SIG SxP)

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Pharmaceutical statistics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Training the next generation of pharmacometric modelers: a multisector perspective.Journal of pharmacokinetics and pharmacodynamics · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 5 countries.

Andreas KrauseClinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.ORCID 0000-0002-4686-976X
Charlotte KloftDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Germany.
Wilhelm HuisingaComputational Physiology, Institute of Mathematics, University of Potsdam, Germany.
Mats KarlssonDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-1258-8297
José PinheiroQuantitative Sciences, Janssen Pharmaceutical Companies of Johnson and Johnson, Titusville, New Jersey.
Robert BiesDepartment of Pharmaceutical Sciences, School of Pharmacy, State University of New York at Buffalo, New York.ORCID 0000-0003-3818-2252
James RogersStatistical Modeling and Data Sciences, Metrum Research Group, Tariffvile, Connecticut.
France MentréIAME, UMR1137, Inserm and Université de Paris Diderot, Paris, France.ORCID 0000-0002-7045-1275
Bret J MusserBiostatistics and Data Management, Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
ASA Special Interest Group on Statistics and Pharmacometrics/ASA Special Interest Group on Statistics and Pharmacometrics (SIG SxP)
Freie Universität Berlin · DEIdorsia (Switzerland) · CHInserm · FRJohnson & Johnson (United States) · USMetrum Research Group (United States) · USRegeneron (United States) · USUniversity at Buffalo, State University of New York · USUniversity of Potsdam · DEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CurriculumDrug Development

Identifiers

PMID30932340
OpenAlexW2933304798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.